If the company secures regulatory approval, Eli Lilly will manufacture its weight-loss pill orforglipron in the United States, CEO David Ricks told Fox Business in a Friday interview — a day after the drugmaker reported Phase 3 trial results for the investigational oral GLP-1. While there have been shortages and supply constraints for injectable GLP-1 medicines, Ricks said it will be "easier" for Lilly to manufacture orforglipron at scale in the U.S. because it is an oral drug. At the same time, he called it a "complicated, multi-step process" to make the pill. "Nothing is easy in medicine making — we have to be super precise," according to Ricks. "We're building the largest what we call API factory, which is active pharmaceutical ingredient, in the history of the country." In February, Lilly announced a $27 billion investment to build four new U.S. pharmaceutical manufacturing sites — three for active pharmaceutical ingredients (APIs) and one to manufacture injectable products and devices.